

JKW #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Joerg Schneider, Sarah C. Gilbert, Carolyn M. Hannan and Adrian V.S. Hill

Application No.: 10/088,677 Group Art Unit: 1645

371(c) Date: May 31, 2002 Examiner: Robert A. Zeman

Confirmation No.: 4825

Title: USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+T CELL IMMUNE RESPONSE TO ANTIGEN

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

September 15, 2006 Marianne Lentini

Date

Signature

MARIANNE LENTINI

Typed or printed name of person signing certificate

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Third Supplemental Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:
 a Statement under 37 CFR 1.97(e), as checked below, or
 a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:
 a Statement under 37 CFR 1.97(e), as checked below, and
 a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application file.
(Filed after payment of issue fee)

09/20/2006 RHEBRAHT 00000001 10088677
180.00 OP
01 FC:1806

Statement Under 37 CFR 1.97(e)

- [] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

- [X] Copies of the cited references, B6-B11 and C32-C145, are enclosed.
- [X] Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- [] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- [] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- [X] The "concise explanation" requirement (non-English references) for references B10, B11 and C95 under 37 CFR 1.98(a)(3) is satisfied by:
 - [] the explanation provided on the attached sheet.
 - [] the explanation provided in the Specification.
 - [] submission of the enclosed International Search Report.
 - [] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- [X] the enclosed English language abstracts.

[] Applicant requests that the following non-published pending applications be considered:
(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner _____

Date _____

[] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
[] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Eric M. Balicky
Registration No.: 57,020
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: *September 15, 2006*

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
SEP 19 2006 <i>(Use several sheets if necessary)</i>	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
		GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002	
September 15, 2006 (Use several sheets if necessary)	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

FOREIGN PATENT DOCUMENTS

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
C32	Ada, G., "Do Cytotoxic T Lymphocytes Clear Some HIV/SIV Infections?", <i>J. Med. Primatol.</i> 25(3):158-162 (1996).			
C33	Afonso, C.L., <i>et al.</i> , "The Genome of Fowlpox Virus," <i>J. Virol.</i> 74(8):3815-3831 (2000).			
C34	Aidoo, M., <i>et al.</i> , "Recombinant Vaccinia Viruses for the Characterization of <i>Plasmodium falciparum</i> -specific Cytotoxic T Lymphocytes: Recognition of Processed Antigen Despite Limited Re-Stimulation Efficacy," <i>Intl. Immunol.</i> 9(5):731-737 (1997).			
C35	Aidoo, M., <i>et al.</i> , "Identification of Conserved Antigenic Components for a Cytotoxic T Lymphocyte-inducing Vaccine Against Malaria," <i>Lancet</i> 345(8956):1003-1007 (1995).			
C36	Allsopp, C.E.M., <i>et al.</i> , "Comparison of Numerous Delivery Systems for the Induction of Cytotoxic T Lymphocytes by Immunization," <i>Eur. J. Immunol.</i> 26:1951-1959 (1996).			
C37	Blanchard, T.J., <i>et al.</i> , "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine," <i>J. Gen. Virol.</i> 79:1159-1167 (1998).			
C38	Blanchard, T., <i>et al.</i> , "Future Vaccines for HIV," <i>Lancet</i> 348(9043):1741 (1996).			
C39	Boulanger, D., <i>et al.</i> , "Morphogenesis and Release of Fowlpox Virus," <i>J. Gen. Virol.</i> 81:675-687 (2000).			
C40	Boulanger, D., <i>et al.</i> , "The 131-Amino-Acid Repeat Region of the Essential 39-Kilodalton Core Protein of Fowlpox Virus FP9, Equivlant to Vaccinia Virus A4L Protein, Is Nonessential and Highly Immunogenic," <i>J. Virol.</i> 72(1):170-179 (1998).			
C41	Boursnell, M.E.G., <i>et al.</i> , "A Fowlpox Virus Vaccine Vector with Insertion Sites in the Terminal Repeats: Demonstration of its Efficacy Using the Fusion Gene of Newcastle Disease Virus," <i>Vet. Microbiol.</i> 23:305-316 (1990).			
C42	Boursnell, M.E.G., <i>et al.</i> , "Insertion of the Fusion Gene from Newcastle Disease Virus into a Non-essential Region in the Terminal Repeats of Fowlpox Virus and Demonstration of Protective Immunity Induced by the Recombinant," <i>J. Gen. Virol.</i> 71:621-628 (1990).			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Joerg Schneider	
September 15, 2006 (Use several sheets if necessary)	EXAMINER Robert A. Zeman	371(C) DATE May 31, 2002
		CONFIRMATION NO. 4825
		GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C43	Boyle, D.B. and Heine, H.G., "Recombinant Fowlpox Virus Vaccines for Poultry," <i>Immunol. Cell Biol.</i> 71:391-397 (1993).	
C44	Boyle, D.B., <i>et al.</i> , "Comparison of Field and Vaccine Strains of Australian Fowlpox Viruses," <i>Arch. Virol.</i> 142:737-748 (1997).	
C45	Brooks, J.V., <i>et al.</i> , "Boosting Vaccine for Tuberculosis," <i>Infect. Immun.</i> 69(4): 2714-2717 (2001).	
C46	Brossart, P., <i>et al.</i> , "Virus-Mediated Delivery of Antigenic Epitopes into Dendritic Cells as a Means to Induce CTL," <i>J. Immunol.</i> 158:3270-3276 (1997).	
C47	Campbell, J.I.A., <i>et al.</i> , "Tandem Repeated Sequences within the Terminal Region of the Fowlpox Virus Genome," <i>J. Gen. Virol.</i> 70:145-154 (1989).	
C48	Carroll, M.W., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: A Murine Tumor Model," <i>Vaccine</i> 15(4):387-394 (1997).	
C49	Carter, B.J., <i>et al.</i> , "Gene Therapy as Drug Development," <i>Mol. Therapy</i> 1(3):211-212 (2000).	
C50	Carvalho, L.J.M., <i>et al.</i> , "Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and Prospects," <i>Scand. J. Immunol.</i> 56:327-343 (2002).	
C51	Castelli, C., <i>et al.</i> , "Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8 ⁺ Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 181:363-368 (1995).	
C52	Conry, R.M., <i>et al.</i> , "Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients," <i>Clin. Cancer Res.</i> 8:2782-2787 (2002).	
C53	Coupar, B.E.H., <i>et al.</i> , "Restriction Endonuclease Mapping of the Fowlpox Virus Genome," <i>Virology</i> 179:159-167 (1990).	
C54	Dale, C.J., <i>et al.</i> , "Induction of HIV-1-Specific T-Helper Responses and Type 1 Cytokine Secretion Following Therapeutic Vaccination of Macaques with a Recombinant Fowlpoxvirus Co-expressing Interferon-Gamma," <i>J. Med. Primatol.</i> 29:240-247 (2000).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
C55	Davis, H.L., <i>et al.</i> , "DNA-Mediated Immunization to Hepatitis B Surface Antigen: Longevity of Primary Response and Effect of Boost," <i>Vaccine</i> 14(9):910-915 (1996).			
C56	Denis, O., <i>et al.</i> , "Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+ and CD8+ T-Cell Epitopic Repertoire Broader than that Stimulated by <i>Mycobacterium tuberculosis</i> H37Rv Infection," <i>Infect. Immun.</i> 66(4):1527-1533 (1998).			
C57	Doolan, D.L., <i>et al.</i> , "Circumventing Genetic Restriction of Protection against Malaria with Multigene DNA Immunization: CD8 ⁺ T Cell-, Interferon γ -, and Nitric Oxide-Dependent Immunity," <i>J. Exp. Med.</i> 183(4):1739-1746 (1996).			
C58	Doolan, D.L. and Hoffman, S.L., "The Complexity of Protective Immunity Against Liver-Stage Malaria," <i>J. Immunol.</i> 165(3):1453-1462 (2000).			
C59	Drexler, I., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara Replicates in Baby Hamster Kidney Cells, a Potential Host for Virus Propagation, but not in Various Human Transformed and Primary Cells," <i>J. Gen. Virol.</i> 79:347-352 (1998).			
C60	Egan, M.A., <i>et al.</i> , "Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytolytic T Lymphocyte Responses in Seronegative Adults by a Nonreplicating, Host-Range-Restricted Canarypox Vector (ALVAC) Carrying the HIV-1 _{MN} env Gene," <i>J. Infect. Dis.</i> 171:1623-1627 (1995).			
C61	Franchini, G., <i>et al.</i> , "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but not HIV-2 Recombinant <i>Salmonella</i> Vaccines, Induce Long-lasting Protection in Rhesus Macaques," <i>AIDS Res. Hum. Retroviruses</i> 11(8):909-920 (1995).			
C62	Fuller, D.H., <i>et al.</i> , "Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-immunized Rhesus Macaques," <i>Vaccine</i> 15(8):924-926 (1997).			
C63	Fuller, D.H., <i>et al.</i> , "Gene Gun-Based Nucleic Acid Immunization Alone or in Combination with Recombinant Vaccinia Vectors Suppresses Virus Burden in Rhesus Macaques Challenged with a Heterologous SIV," <i>Immunol. Cell Biol.</i> 75(4):389-396 (1997).			
C64	Gallimore, A., <i>et al.</i> , "Early Suppression of SIV Replication By CD8 ⁺ <i>nef</i> -specific Cytotoxic T Cells in Vaccinated Macaques," <i>Nature Med.</i> 1(11):1167-1173 (1995).			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
			GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C65	Greenspan, N.S. and DiCera, E., "Defining Epitopes: It's not as Easy as it Seems," <i>Nature Biotechnol.</i> 17:936-937 (1999).
C66	Grosenbach, D.W., <i>et al.</i> , "Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects," <i>Cancer Res.</i> 61:4497-4505 (2001).
C67	Hanke, T., <i>et al.</i> , "DNA Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium falciparum</i> : Immunogenicity in Mice," <i>Vaccine</i> 16(4):426-435 (1998).
C68	Hertig, C., <i>et al.</i> , "Field and Vaccine Strains of Fowlpox Virus Carry Integrated Sequences from the Avian Retrovirus, Reticuloendotheliosis Virus," <i>Virol.</i> 235:367-376 (1997).
C69	Hill, A.V.S., <i>et al.</i> , "Common West African HLA Antigens are Associated with Protection from Severe Malaria," <i>Nature</i> 352(6336):595-600 (1991).
C70	Hill, A.V.S., <i>et al.</i> , "DNA-Based Vaccines for Malaria: a Heterologous Prime-Boost Immunisation Strategy," <i>Dev. Biol.</i> 104:171-179 (2000).
C71	Hirsch, V.M., <i>et al.</i> , "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," <i>J. Virol.</i> 70(6):3741-3752 (1996).
C72	HIV CTL Epitopes Table 2: p24. [online], December 1996. Retrieved from the Internet <URL: http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/p24.pdf >.
C73	HIV CTL Epitopes Table 3: p24 [online], December 1999. Retrieved from the Internet <URL: http://hiv-web.lanl.gov/content/immunology/pdf/1999/1/tables/p24.pdf >.
C74	HIV CTL Epitopes Table 4: Pol [online], December 1997. Retrieved from the Internet <URL: http://hiv-web.lanl.gov/content/hiv-db/immunology/PDF/1997/CTL/tables/pol.pdf >.
C75	HIV CTL Epitopes Table 6: gp120. [online], December 1996. Retrieved from the Internet <URL: http://hiv-web-lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp120.pdf >.
C76	HIV CTL Epitopes Table 7: gp41. [online], December 1996. Retrieved from the Internet <URL: http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp41.pdf >.

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

C77	HIV CTL Epitopes Table 8: Nef. [online], December 1996. Retrieved from the Internet <URL: http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/nef.pdf >.
C78	Holder, A., <i>et al.</i> , "Falciparum Malaria MSP1 Workshop: Progress toward MSP1 Vaccine Development and Testing," <i>Malaria Vaccine Initiative at PATH</i> : 1-30 (2000).
C79	Huygen, K., <i>et al.</i> , "Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine," <i>Nature Med.</i> 2(8): 893-898 (1996).
C80	Irvine, K.R., <i>et al.</i> , "Route of Immunization and the Therapeutic Impact of Recombinant Anticancer Vaccines," <i>J. Natl. Cancer Inst.</i> 89(5):390-392 (1997).
C81	Irvine, K., <i>et al.</i> , "Comparison of a CEA-Recombinant Vaccinia Virus, Purified CEA, and an Anti-Idiotype Antibody Bearing the Image of a CEA Epitope in the Treatment and Prevention of CEA-Expressing Tumors," <i>Vaccine Res.</i> 2(2):79-94 (1993).
C82	Johnson, R.P., <i>et al.</i> , "Induction of a Major Histocompatibility Complex Class I-Restricted Cytotoxic T-Lymphocyte Response to a Highly Conserved Region of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 in Seronegative Humans Immunized with a Candidate HIV-1 Vaccine," <i>J. Virol.</i> 68(5):3145-3153 (1994).
C83	Kent, S.J., <i>et al.</i> , "A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-gamma is Safe and Immunogenic in Macaques," <i>Vaccine</i> 18:2250-2256 (2000).
C84	Kent, S.J., <i>et al.</i> , "Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses," <i>AIDS Res. Hum. Retroviruses</i> 10(5):551-560 (1994).
C85	Laidlaw, S.M. and Skinner, M.A., "Comparison of the Genome Sequence of FP9, an attenuated, tissue culture-adapted European strain of <i>Fowlpox virus</i> , with those of virulent American and European viruses," <i>J. Gen. Virol.</i> 85:305-322 (2004).
C86	Laidlaw, S.M., <i>et al.</i> , "Fowlpox Virus Encodes Nonessential Homologs of Cellular Alpha-SNAP, PC-1, and an Orphan Human Homolog of a Secreted Nematode Protein," <i>J. Virol.</i> 72(8):6742-6751 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION September 15, 2006 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
		FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
			GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
C87	Lalvani, A., <i>et al.</i> , "An HLA-based Approach to the Design of a CTL-Inducing Vaccine Against <i>Plasmodium falciparum</i> ," <i>Res. Immunology</i> 145(6):461-468 (1994).		
C88	Lanar, D.E., <i>et al.</i> , "Attenuated Vaccinia Virus-Circumsporozoite Protein Recombinants Confer Protection against Rodent Malaria," <i>Infec. Immun.</i> 64(5):1666-1671 (1996).		
C89	Layton, G.T., <i>et al.</i> , "Induction of Single and Dual Cytotoxic T-Lymphocyte Responses to Viral Proteins in Mice Using Recombinant Hybrid Ty-Virus-Like Particles," <i>Immunology</i> 87(2):171-178 (1996).		
C90	Leong, K.H., <i>et al.</i> , "Selective Induction of Immune Responses by Cytokines Coexpressed in Recombinant Fowlpox Virus," <i>J. Virol.</i> 68(12):8125-8130 (1994).		
C91	Leong, K.H., <i>et al.</i> , "Generation of Enhanced Immune Responses by Consecutive Immunization with DNA and Recombinant Fowl Pox Vectors," <i>Vaccines</i> 95:327-331 (1995).		
C92	Limbach, K.J. and Paoletti, E., "Non-Replicating Expression Vectors: Application in Vaccine Development and Gene Therapy," <i>Epidemiol. Infect.</i> 116:241-256 (1996).		
C93	Mahnel, <i>et al.</i> , "Experiences with Immunization Against Orthopox Viruses of Humans and Animals Using Vaccine Strain MVA," <i>Berliner Und Munchener Tierarztliche Wochenschrift</i> 107(8):253-256 (1994) ABSTRACT ONLY		
C94	Mayr, A. and Malicki, K., "Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus," <i>Zbl. Vet. Med. B</i> B13:1-13 (1966).		
C95	Meyer, H., <i>et al.</i> , "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," <i>J. Gen. Virol.</i> 72:1031-1038 (1991).		
C96	Moorthy, V.S., <i>et al.</i> , "Safety of DNA and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage <i>P. falciparum</i> Malaria in Non-Immune Volunteers," <i>Vaccine</i> 21(17-18):1995-2002 (2003).		
C97	Moorthy, V. and Hill, A.V.S., "Malaria Vaccines," <i>Br. Med. Bull.</i> 62:59-72 (2002).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
		GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C98	Moreno, A., <i>et al.</i> , "Cytotoxic CD4+ T Cells From a Sporozoite-Immunized Volunteer Recognize the <i>Plamodium falciparum</i> CS Protein," <i>Int. Immunol.</i> 3(10):997-1003 (1991).
C99	Moss, B., "Genetically Engineered Poxviruses for Recombinant Gene Expression, Vaccination, and Safety," <i>Proc. Natl. Acad. Sci. USA</i> 93:11341-11348 (1996).
C100	Moss, B., <i>et al.</i> , "Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates." In <i>Novel Strategies in Design and Production of Vaccines</i> , S.Cohen <i>et al.</i> , eds. (NY:Plenum Press), pp. 7-13 (1996).
C101	Müller, H.-M., <i>et al.</i> , "Thrombospondin Related Anonymous Protein (TRAP) of <i>Plasmodium falciparum</i> Binds Specifically to Sulfated Glycoconjugates and to HepG2 Hepatoma Cells Suggesting a Role for this Molecule in Sporozoite Invasion of Hepatocytes," <i>EMBO J.</i> 12(7):2881-2889 (1993).
C102	Murata, K., <i>et al.</i> , "Characterization of <i>in Vivo</i> Primary and Secondary CD8+ T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses," <i>Cell. Immunol.</i> 173(1):96-107 (1996).
C103	Nardin, E.H. and Nussenzweig, R.S., "T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic Stages," <i>Annu. Rev. Immunol.</i> 11:687-727 (1993).
C104	NCBI Accession No. AF198100, "Fowlpox virus, complete genome," [online], March 2000. [retrieved on 2006-09-14] Retrieved from the Internet <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=7271507 >.
C105	Ohminami, H., <i>et al.</i> , "HLA Class I-Restricted Lysis of Leukemia Cells by a CD8+ Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide," <i>Blood</i> 95(1):286-293 (2000).
C106	Paoletti, E., "Applications of Pox Virus Vectors to Vaccination: An Update," <i>Proc. Natl. Acad. Sci. USA</i> 93:11349-11353 (1996).
C107	Pialoux, G., <i>et al.</i> , "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) Followed by a Recombinant Glycoprotein 160 (MN/LAI)," <i>AIDS Res. Hum. Retroviruses.</i> 11(3):373-381 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
			GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C108	Pollitt, E., et al., "Nucleotide Sequence of the 4.3 kbp BamHI-N Fragment of Fowlpox Virus FP9," <i>Virus Genes</i> 17(1):5-9 (1998).
C109	Qingzhong, Y., et al., "Protection Against Turkey Rhinotracheitis Pneumovirus (TRTV) Induced by a Fowlpox Virus Recombinant Expressing the TRTV Fusion Glycoprotein (F)," <i>Vaccine</i> 12(6):569-573 (1994).
C110	Ramarathinam, L., et al., "Multiple Lineages of Tumors Express a Common Tumor Antigen, P1A, but they are not Cross-Protected," <i>J. Immunol.</i> 155: 5323-5329 (1995).
C111	Rimoldi, D., et al., "Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma," <i>J. Immunol.</i> , 165:7253-7261 (2000).
C112	Rodrigues, M., et al., "Influenza and Vaccinia Viruses Expressing Malaria CD8 ⁺ T and B Cell Epitopes," <i>J. Immunol.</i> 153(10):4636-4648 (1994).
C113	Rodriguez, D., et al., "Regulated Expression of Nuclear Genes by T3 RNA Polymerase and lac Repressor, Using Recombinant Vaccinia Virus Vectors," <i>J. Virol.</i> 64(10):4851-4857 (1990).
C114	Schödel, F., et al., "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," <i>J. Exp. Med.</i> 180(3):1037-1046 (1994).
C115	Sedegah, M., et al., "Protection against Malaria by Immunization with Plasmid DNA Encoding Circumsporozoite Protein," <i>Proc. Natl. Acad. Sci. USA</i> 91(21):9866-9870 (1994).
C116	Seguin, M.C., et al., "Induction of Nitric Oxide Synthase Protects against Malaria in Mice Exposed to Irradiated <i>Plasmodium berghei</i> Infected Mosquitoes: Involvement of Interferon γ and CD8 ⁺ T Cells," <i>J. Exp. Med.</i> 180(1):353-358 (1994).
C117	Sequence Alignment of SEQ ID NO: 4 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43245 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, et al.

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
			GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
C118	Sequence Alignment of SEQ ID NO: 2 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43244 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>		
C119	Sequence Alignment of SEQ ID NO: 6 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43243 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>		
C120	Shaw, I., and Davison, T.F., "Protection From IBDV-induced Bursal Damage by a Recombinant Fowlpox Vaccine, fpIBD1, is Dependent on the Titre of Challenge Virus and Chicken Genotype," <i>Vaccine</i> 18:3230-3241 (2000).		
C121	Skinner, M.A., <i>et al.</i> , "Fowlpox Virus as a Recombinant Vaccine Vector for use in Mammals and Poultry," <i>Expert Rev. Vaccines</i> 4(1):63-76 (2005).		
C122	Somogyi, P., <i>et al.</i> , "Fowlpox Virus Host Range Restriction: Gene Expression, DNA Replication, and Morphogenesis in Nonpermissive Mammalian Cells," <i>Virology</i> 197:439-444 (1993).		
C123	Stoute, J.A., <i>et al.</i> , "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium falciparum</i> Malaria," <i>N. Engl. J. Med.</i> 336(2):86-91 (1997).		
C124	Sutter, G., <i>et al.</i> , "A Recombinant Vector Derived From the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," <i>Vaccine</i> 12(11):1032-1040 (1994).		
C125	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," <i>Proc. Natl. Acad. Sci. USA</i> 89:10847-10851 (1992).		
C126	SYFPEITHI Database, "Find Your Motif," [online], [retrieved on 2006-09-01]. Retrieved from the Internet <URL: http://www.syfpeithi.de/Scripts/MHCServer.dll/FindYourMotif.htm >.		
C127	Tanghe, A., <i>et al.</i> , "Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein Boosting," <i>Infect. Immun.</i> 69(5):3041-3047 (2001).		
C128	Tartaglia, J., <i>et al.</i> , "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," <i>Virology</i> 188(1):217-232 (1992).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider	371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825
			GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C129	Tartaglia, J., <i>et al.</i> , "Protection of Cats against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL," <i>J. Virol.</i> 67(4):2370-2375 (1993).
C130	Tascon, R.E., <i>et al.</i> , "Vaccination Against Tuberculosis by DNA Injection," <i>Nature Med.</i> 2(8): 888-892 (1996).
C131	Taylor, J. and Paoletti, E., "Fowlpox Virus as a Vector in Non-Avian Species," <i>Vaccine</i> 6:466-468 (1988).
C132	Taylor, J., <i>et al.</i> , "Protective Immunity Against Avian Influenza Induced by Fowlpox Virus Recombinant," <i>Vaccine</i> 6:504-508 (1988).
C133	Taylor, J., <i>et al.</i> , "Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species," <i>Vaccine</i> 6(6):497-503 (1988).
C134	Thomson, S.A., <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-1723 (1998).
C135	Tsang, K.Y., <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990 (1995).
C136	Tsuji, M., <i>et al.</i> , "CD4 ⁺ Cytolytic T Cell Clone Confers Protection against Murine Malaria," <i>J. Exp. Med.</i> 172(5):1353-1357 (1990).
C137	Tsukamoto, K., <i>et al.</i> , "Dual-Viral Vector Approach Induced Strong and Long-Lasting Protective Immunity against Very Virulent Infectious Bursal Disease Virus," <i>Virology</i> 269(2):257-267 (2000).
C138	Van den Eynde, B. and van der Bruggen, P., "Peptide Database," <i>Cancer Immunity</i> , March 2001, online, retrieved from the Internet on June 23, 2003. <URL: http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm >
C139	Walker, B.D., <i>et al.</i> , "Long-term Culture and Fine Specificity of Human Cytotoxic T-Lymphocyte Clones Reactive with Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 86:9514-9518 (1989).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000	APPLICATION NO. 10/088,677	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002
September 15, 2006 (Use several sheets if necessary)		EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
C140	Wang, M., <i>et al.</i> , "Active Immunotherapy of Cancer with a Nonreplicating Recombinant Fowlpox Virus Encoding a Model Tumor-associated Antigen," <i>J. Immunol.</i> 154(9):4685-4692 (1995).			
C141	Wang, R., <i>et al.</i> , "Induction of CD4 ⁺ T Cell-dependent CD8 ⁺ Type 1 Responses in Humans by a Malaria DNA Vaccine," <i>Proc. Natl. Acad. Sci. USA</i> 98(19):10817-10822 (2001).			
C142	Watson, J.C. and Peter, G., "General Immunization Practices," in <i>Vaccines</i> , Plotkin, S.A. and Orenstein, eds., (W.B. Saunders) pp. 47-73 (1999).			
C143	Wizel, B., <i>et al.</i> , "Irradiated Sporozoite Vaccine Induces HLA-B8-Restricted Cytotoxic T Lymphocyte Responses against Two Overlapping Epitopes of the <i>Plasmodium falciparum</i> Sporozoite Surface Protein 2," <i>J. Exp. Med.</i> 182(5):1435-1445 (1995).			
C144	Zhu, X., <i>et al.</i> , "Functions and Specificity of T Cells Following Nucleic Acid Vaccination of Mice Against <i>Mycobacterium tuberculosis</i> Infection," <i>J. Immunol.</i> 158:5921-5926 (1997).			
C145	Zorn, E. and Hercend, T., "A Natural Cytotoxic T Cell Response in a Spontaneously Regressing Human Melanoma Targets a Neoantigen Resulting from a Somatic Point Mutation," <i>Eur. J. Immunol.</i> 29:592-601 (1999).			
C146				

EXAMINER	DATE CONSIDERED
----------	-----------------